Dracenax is indicated only for early postmenopausal HR positive breast cancer.

Dracenax contains __ mg of Letrozole.

What is the shelf life of Dracenax?

Dracenax is contraindicated to the following except for one.

These are the most frequently reported adverse reactions of patients taking Dracenax.

There is no dosage adjustment recommended for mild to moderate hepatic impairment for patients taking Dracenax.

Where is Dracenax manufactured?

Dracenax has demonstrated efficacy in patients with hormone receptor negative breast cancer.

There is no clinical experience to date on the use of Dracenax in combination of other anti-cancer agents.

Dracenax can be used in which line of breast cancer treatment?

Dracenax inhibits the aromatase enzyme by competitively binding to the hem of the aromatase cytochrome P450, resulting in the rapid increase of estrogen biosynthesis in all tissues where present.

Letrozole significantly reduced the overall risk of recurrence versus tamoxifen by how many percent in early breast cancer?

Encircle the options on the use of Letrozole in breast cancer.

Letrozole reduced the overall recurrence by __% regardless of nodal status/prior chemotherapy in the extended adjuvant setting.

Letrozole significantly reduced the risk of distant metastasis versus tamoxifen by how many percent in early breast cancer?

___  is a multinational, phase 3, randomized, double blind, clinical trial conducted in more than 8,000 patients.

In the ___ study, patients with early-stage breast cancer receive 5 years of Tamoxifen and then switched to either the aromatase inhibitor Letrozole or placebo.

Letrozole can also be used in the neoadjuvant setting.

BONUS: Which 3 NCSM components must be mentioned in the Power Call?